

2021

Guide to Occupational Exposure Values

Compiled by
ACGIH®



Signature Publications

ISBN: 978-1-607261-48-3

© 2021 by ACGIH®. This book is fully protected by copyright and no part of it may be reproduced in any form or by any means — graphic, electronic, or mechanical including photocopying, recording, taping, or information storage and retrieval systems — without written permission from ACGIH®, 3640 Park 42 Drive, Cincinnati, Ohio 45241.

Published in the United States of America by
ACGIH®
3640 Park 42 Drive
Cincinnati, Ohio 45241
acgih.org

Printed in the United States

2021

Guide to Occupational Exposure Values

Compiled by
ACGIH®



Signature Publications

INTRODUCTION

The *Guide to Occupational Exposure Values* is a readily accessible reference for comparison of published values from ACGIH®; the U.S. Occupational Safety and Health Administration (OSHA); the U.S. National Institute for Occupational Safety and Health (NIOSH); Deutsche Forschungsgemeinschaft (DFG), Federal Republic of Germany, Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area; the American Industrial Hygiene Association (AIHA); and Occupational Alliance for Risk Science (OARS). Provided below are the sources of the values cited in this *Guide*, including publication dates, and the uniform resource locator (URL) if verified online (Reviewed 2019).

- ACGIH® Threshold Limit Values (TLVs®) for Chemical Substances
 - *2021 TLVs® and BEIs®: Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices*. ACGIH®, Cincinnati, OH (2021).
- OSHA Permissible Exposure Limits (PELs)
 - Occupational Safety and Health Administration (OSHA): Occupational Safety and Health Standards, Toxic and Hazardous Substances, Limits for Air Contaminants. Specified in Tables Z-1, Z-2, and Z-3. Title 29 CFR 1910.1000–1910.1200. Reviewed at: <https://www.osha.gov/dsg/annotated-pels/index.html>.
- NIOSH Recommended Exposure Limits (RELs)
 - NIOSH Pocket Guide to Chemical Hazards: Introduction. Available online at: <http://www.cdc.gov/niosh/npg/pgintrod.html> (Reviewed 2020).
 - See also: Ludwig HR; Cairelli SG; Whalen JJ (Eds): Documentation for Immediately Dangerous to Life or Health Concentrations (IDLH): Introduction. NTIS Pub. No. PB-94-195047 (1994). Available online at: <http://www.cdc.gov/niosh/idlh/idlhintr.html>.
 - See also: Wittaker C; Rice F; McKernan L; et al.: Current intelligence bulletin 68: NIOSH chemical carcinogen policy. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH), DHHS, Publication No. 2017-100 (2017). Available online at: <https://www.cdc.gov/niosh/docs/2017-100/pdf/2017-100.pdf>.
- DFG Maximum Concentrations at the Workplace (MAKs)
 - List of MAK and BAT Values 2020: Maximum Concentrations and Biological Tolerance Values at the Workplace. Report No. 54. Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, FRG (2020).
- AIHA Workplace Environmental Exposure Levels (WEELs™)
- OARS Workplace Environmental Exposure Levels (WEELs™)
 - Occupational Alliance for Risk Science (OARS) Workplace Environmental Exposure Levels (WEELs™) managed by Toxicological Excellence for Risk Assessment (TERA), Cincinnati, OH. Available online at tera.org/OARS/index.html (Reviewed 2021).

The *Guide* also includes those carcinogens found in the occupational environment that are identified by the above organizations and by the U.S. Environmental Protection Agency (EPA), the International Agency for Research on Cancer (IARC), and the U.S. National Toxicology Program (NTP). In addition to those sources cited above, the following were also used in preparing this *Guide* (Reviewed 2021).

- U.S. EPA Integrated Risk Information System (IRIS) database. A–Z List of Substances. Online at: <https://cfpub.epa.gov/ncea/iris2/atoz.cfm>.
- Agents Classified by the IARC Monographs, Volumes 1–124. IARC, Lyon, France (1987–2020). Available online at: <http://monographs.iarc.fr/agents-classified-by-the-iarc/> (Reviewed 2020).
- Report on Carcinogens, 14th Ed., U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, Research Triangle Park, NC (2016). Available online at: <http://ntp.niehs.nih.gov/pubhealth/roc/index-1.html> (Reviewed 2016).

The *Guide to Occupational Exposure Values* is intended as a companion document to the ACGIH® annual *Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices (TLVs® and BEIs®)* book, specifically the section on TLVs® for Chemical Substances in the Work Environment.

The following pages provide “Definitions, Abbreviations, Terms, and Coding,” the MAK “Peak Exposure Limitation Categories,” the MAK “Pregnancy Risk Group Classifications,” and the MAK “Germ Cell Mutagens Classifications.”

Editor’s note: The double entries that were previously included in this publication were eliminated effective with the 2006 edition. The entry in this publication will correspond to that carried in the *TLVs® and BEIs®* book, e.g., 2-butoxyethanol rather than ethylene glycol monobutyl ether. When ACGIH® does not recommend a TLV® and two or more jurisdictions (e.g., MAK and IARC) list a chemical substance with separate synonyms, ACGIH® will generally use the ChemIDplus database available on the ToxNet website (<http://toxnet.nlm.nih.gov/>) maintained by the U.S. National Library of Medicine. ChemIDplus is a database of over 370,000 chemicals, which contains names and synonyms as well as chemical formulae and structures. Whichever synonym ChemIDplus uses as the primary name attached to a specific CAS number is the name generally listed in this publication. In all cases, the removed synonym is listed with its primary entry and with its respective CAS number in the CAS Number Index section of this publication.

DEFINITIONS, ABBREVIATIONS, TERMS, AND CODING

Carcinogenicity Categories

U.S. Environmental Protection Agency (EPA)

NOTE: The rationale and methods used to develop the carcinogenicity classifications EPA-A through EPA-E are found in the 1986 *Risk Assessment Guidelines* (EPA/600/8-87/045). The categories, EPA-K, EPA-L, EPA-CBD, and EPA-UL, were developed under the 1996 *Proposed Guidelines for Carcinogen Risk Assessment* (*Federal Register* 61[79]:17960-18011, April 23, 1996). Further to its updating of risk assessment guidelines, EPA issued a revised draft *Guidelines for Carcinogen Risk Assessment* (NCEA-F-0644; July 1999), which resulted in slightly different descriptors. In 2005, the agency published the final version of *Guidelines for Carcinogen Risk Assessment* (EPA/630/P-03-001 B), which contained refined descriptors for summarizing weight of evidence for human carcinogenic potential. All four risk assessment guidelines may be found online at: <http://www.epa.gov/risk>. In all instances, the user is referred to the online IRIS Guidance Documents found on the EPA website: <http://www.epa.gov/iris> and the online Toxicological Reviews and Support Documents available at: <http://cfpub.epa.gov/ncea/iris> for further carcinogenicity discussion and for information on long-term toxic effects other than carcinogenicity. In all cases, the most current carcinogenicity assessment will be listed in this publication.

EPA-A: Human Carcinogen — Sufficient evidence from epidemiologic studies to support a causal association between exposure and cancer.

-B: Probable Human Carcinogen — Weight of evidence of human carcinogenicity based on epidemiologic studies is limited; agents for which weight of evidence of carcinogenicity based on animal studies is sufficient.

Two subgroups:

-B1: Limited evidence of carcinogenicity from epidemiologic studies.

-B2: Sufficient evidence from animal studies; inadequate evidence or no data from epidemiologic studies.

-C: Possible Human Carcinogen — Limited evidence of carcinogenicity in animals in the absence of human data.

-D: Not Classifiable as to Human Carcinogenicity — Inadequate human and animal evidence of carcinogenicity or no data are available.

-E: Evidence of Noncarcinogenicity for Humans — No evidence for carcinogenicity in at least two adequate animal tests in different species or in both adequate epidemiologic and animal studies.

Under the 1996 Draft Guidelines, when the available tumor effects and other key data are adequate to demonstrate carcinogenic potential convincingly for humans, EPA-K or EPA-L are appropriate descriptors.

EPA-K: Known Human Carcinogens — Agents *known* to be carcinogenic in humans based on either epidemiologic evidence or a combination of epidemiologic and experimental evidence, demonstrating causality between human exposure and cancer;

OR

Agents that should be treated *as if* they were *known* human carcinogens, based on a combination of epidemiologic data showing a plausible causal association (not demonstrating it definitively) and strong experimental evidence.

OCCUPATIONAL EXPOSURE VALUES

vi

-L: Likely to Produce Cancer in Humans — Agents that are *likely* to produce cancer in humans due to the production or anticipated production of tumors by modes of action that are relevant or assumed to be relevant to human carcinogenicity. Modifying descriptors for particularly high or low ranking in the “known/likely” group can be applied based on scientific judgment and experience and are as follows:

- Agents that are *likely* to produce cancer in humans based on data that are at the high end of the weights of evidence typical of this group.
- Agents that are *likely* to produce cancer in humans based on data that are at the low end of the weights of evidence typical of this group.

-CBD: Cannot Be Determined — This descriptor is appropriate when available tumor effects or other key data are suggestive or conflicting or limited in quantity and, thus, are not adequate to convincingly demonstrate carcinogenic potential for humans. In general, further agent specific and generic research and testing are needed to be able to describe human carcinogenic potential. The descriptor *cannot be determined* is used with a subdescriptor that captures the rationale:

- Agents whose carcinogenic potential *cannot be determined*, but for which there is suggestive evidence that raises concern for carcinogenic effects.
- Agents whose carcinogenic potential *cannot be determined* because the existing evidence is composed of *conflicting data* (e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm any concern).
- Agents whose carcinogenic potential *cannot be determined* because there are inadequate data to perform an assessment.

- Agents whose carcinogenic potential *cannot be determined* because no data are available to perform an assessment.

-NL: Not Likely to be Carcinogenic in Humans — This descriptor is appropriate when experimental evidence is satisfactory for deciding that there is no basis for human hazard concern, as follows (in the absence of human data suggesting a potential for cancer effects):

- Agents *not likely* to be carcinogenic to humans because they have been evaluated in at least two well-conducted studies in two appropriate animal species without demonstrating carcinogenic effects.
- Agents *not likely* to be carcinogenic to humans because they have been appropriately evaluated in animals and show only carcinogenic effects that have been shown not to be relevant to humans (e.g., showing only effects in the male rat kidney due to accumulation of $\alpha_2\text{u}$ -globulin).
- Agents *not likely* to be carcinogenic to humans when carcinogenicity is dose or route dependent. For instance, not likely below a certain dose range (categorized as *likely* above that range) or *not likely* by a certain route of exposure (may be categorized as *likely* by another route of exposure). To qualify, agents will have been appropriately evaluated in animal studies and the only effects show a dose range or route limitation or a route limitation is otherwise shown by empirical data.

Under the 1999 revised draft Guidelines, the following descriptors were issued; however, the descriptors are only presented in the context of a weight-of-evidence-narrative. [Editor’s note: The “short hand” used within this *Guide* (e.g., EPA-K) to indicate descriptors used within the 1996 and 1999 draft Guidelines were developed to accommodate the page format only.] The reader is referred to the current EPA evaluation for a complete discussion of substance in question.

EPA-CaH: Carcinogenic to Humans — This descriptor is appropriate when there is convincing epidemiologic evidence demonstrating causality between human exposure and cancer. This descriptor is also appropriate when there is an absence of conclusive epidemiologic evidence to clearly establish a cause and effect relationship between human exposure and cancer, but there is compelling evidence of carcinogenicity in animals and mechanistic information in animals and humans demonstrating similar mode(s) of carcinogenic action. It is used when all of the following conditions are met:

- There is evidence in a human population(s) of association of exposure to the agent with cancer, but not enough to show a causal association;
- There is extensive evidence of carcinogenicity;
- The mode(s) of carcinogenic action and associated key events have been identified in animals; and
- The key events that precede the cancer response in animals have been observed in the human population(s) that also show evidence of an association of exposure to the agent with cancer.

-L: Likely to be Carcinogenic to Humans — This descriptor is appropriate when the available tumor effects and other key data are adequate to demonstrate carcinogenic potential to humans. Adequate data are within a spectrum. At one end is evidence for an association between human exposure to the agent and cancer and strong experimental evidence of carcinogenicity in animals; at the other, with no human data, the weight of experimental evidence shows animal carcinogenicity by a mode or modes of action that are relevant or assumed to be relevant to humans.

-S: Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human Carcinogenic Potential — This descriptor is appropriate when the evidence from human or animal data is suggestive of carcinogenicity, which raises a

concern for carcinogenic effects but is judged not sufficient for a conclusion as to human carcinogenic potential. Examples of such evidence may include: a marginal increase in tumors that may be exposure-related, or evidence is observed only in a single study, or the only evidence is limited to certain high background tumors in one sex of one species. Dose–response assessment is not indicated for these agents. Further studies would be needed to determine human carcinogenic potential.

-I: Data are Inadequate for an Assessment of Human Carcinogenic Potential — This descriptor is used when available data are judged inadequate to perform an assessment. This includes a case when there is a lack of pertinent or useful data or when existing evidence is conflicting, e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm a concern.

-NL: Not Likely to be Carcinogenic to Humans — This descriptor is used when the available data are considered robust for deciding that there is no basis for human hazard concern. The judgment may be based on the following:

- Extensive human experience that demonstrates lack of carcinogenic effect (e.g., phenobarbital).
- Animal evidence that demonstrates lack of carcinogenic effect in at least two well-designed and well-conducted studies in two appropriate animal species (in the absence of human data suggesting a potential for cancer effects).
- Extensive experimental evidence showing that the only carcinogenic effects observed in animals are not considered relevant to humans (e.g., showing only effects in the male rat kidney due to accumulation of α_2 u-globulin).
- Evidence that carcinogenic effects are not likely by a particular route of exposure (Section 2.3.3.).

OCCUPATIONAL EXPOSURE VALUES

viii

- Evidence that carcinogenic effects are not anticipated below a defined dose range.

Under the 2005 *Guidelines for Carcinogen Risk Assessment* (EPA/630/P-03/001 B), the following descriptors were issued; however, the descriptors are only presented in the context of a weight-of-evidence-narrative. [Editor's note: The "short hand" (e.g., EPA-CaH) used within this *Guide* to indicate the 2005 descriptors was developed to accommodate the page format of this *Guide* only.] The reader is referred to the individual IRIS evaluation for a complete discussion of the substance in question.

EPA-CaH: Carcinogenic to Humans — This descriptor indicates strong evidence of human carcinogenicity. It covers different combinations of evidence.

- This descriptor is appropriate when there is convincing epidemiologic evidence of a causal association between human exposure and cancer.
- Exceptionally, this descriptor may be equally appropriate with a lesser weight of epidemiologic evidence that is strengthened by other lines of evidence. It can be used when all of the following conditions are met: (a) there is strong evidence of an association between human exposure and either cancer or the key precursor events of the agent's mode of action but not enough for a causal association, and (b) there is extensive evidence of carcinogenicity in animals, and (c) the mode(s) of carcinogenic action and associated key precursor events have been identified in animals, and (d) there is strong evidence that the key precursor events that precede the cancer response in animals are anticipated to occur in humans and progress to tumors, based on available biological information. In this case, the narrative includes a summary of both the experimental and epidemiologic information on mode of action and also an indication of the relative weight that each source of information carries, e.g., based on human information, based on limited human and extensive animal experiments.

-L: Likely to Be Carcinogenic to Humans — This descriptor is appropriate when the weight of the evidence is adequate to demonstrate carcinogenic potential to humans but does not reach the weight of evidence for the "Carcinogenic to Humans" descriptor. Adequate evidence consistent with this descriptor covers a broad spectrum. As stated previously, the use of the term "likely" as a weight of evidence descriptor does not correspond to a quantifiable probability. The examples below are meant to represent the broad range of data combinations that are covered by this descriptor; they are illustrative and provide neither a checklist nor a limitation for the data that might support use of this descriptor. Moreover, additional information, e.g., on mode of action, might change the choice of descriptor for the illustrated examples. Supporting data for this descriptor may include:

- an agent demonstrating a plausible (but not definitively causal) association between human exposure and cancer, in most cases with some supporting biological, experimental evidence, though not necessarily carcinogenicity data from animal experiments;
- an agent that has tested positive in animal experiments in more than one species, sex, strain, site, or exposure route, with or without evidence of carcinogenicity in humans;
- a positive tumor study that raises additional biological concerns beyond that of a statistically significant result, for example, a high degree of malignancy, or an early age at onset;
- a rare animal tumor response in a single experiment that is assumed to be relevant to humans; or
- a positive tumor study that is strengthened by other lines of evidence, for example, either plausible (but not definitively causal) association between human exposure and cancer or evidence that the agent or an important

metabolite causes events generally known to be associated with tumor formation (such as DNA reactivity or effects on cell growth control) likely to be related to the tumor response in this case.

-S: Suggestive Evidence of Carcinogenic Potential — This descriptor of the database is appropriate when the weight of evidence is suggestive of carcinogenicity; a concern for potential carcinogenic effects in humans is raised, but the data are judged not sufficient for a stronger conclusion. This descriptor covers a spectrum of evidence associated with varying levels of concern for carcinogenicity, ranging from a positive cancer result in the only study on an agent to a single positive cancer result in an extensive database that includes negative studies in other species. Depending on the extent of the database, additional studies may or may not provide further insights. Some examples include:

- a small, and possibly not statistically significant, increase in tumor incidence observed in a single animal or human study that does not reach the weight of evidence for the descriptor “Likely to Be Carcinogenic to Humans.” The study generally would not be contradicted by other studies of equal quality in the same population group or experimental system (see discussions of *conflicting evidence* and differing results, below);
- a small increase in a tumor with a high background rate in that sex and strain, when there is some but insufficient evidence that the observed tumors may be due to intrinsic factors that cause background tumors and not due to the agent being assessed. (When there is a high background rate of a specific tumor in animals of a particular sex and strain, then there may be biological factors operating independently of the agent being assessed that could be responsible for the development of the observed tumors.) In this case, the reasons for determining that the tumors are not due to the agent are explained;

- evidence of a positive response in a study whose power, design, or conduct limits the ability to draw a confident conclusion (but does not make the study fatally flawed), but where the carcinogenic potential is strengthened by other lines of evidence (such as structure-activity relationships); or
- a statistically significant increase at one dose only, but no significant response at the other doses and no overall trend.

-II: Inadequate Information to Assess Carcinogenic Potential — This descriptor of the database is appropriate when available data are judged inadequate for applying one of the other descriptors. Additional studies generally would be expected to provide further insights. Some examples include:

- little or no pertinent information;
- conflicting evidence, that is, some studies provide evidence of carcinogenicity but other studies of equal quality in the same sex and strain are negative. *Differing results*, that is, positive results in some studies and negative results in one or more different experimental systems, do not constitute *conflicting evidence*, as the term is used here. Depending on the overall weight of evidence, differing results can be considered either suggestive evidence or likely evidence; or
- negative results that are not sufficiently robust for the descriptor, “Not Likely to Be Carcinogenic to Humans.”

-NL: Not Likely to Be Carcinogenic to Humans — This descriptor is appropriate when the available data are considered robust for deciding that there is no basis for human hazard concern. In some instances, there can be positive results in experimental animals when there is strong, consistent evidence that each mode of action in experimental animals does not operate in humans. In

OCCUPATIONAL EXPOSURE VALUES

other cases, there can be convincing evidence in both humans and animals that the agent is not carcinogenic. The judgment may be based on data such as:

- animal evidence that demonstrates lack of carcinogenic effect in both sexes in well-designed and well-conducted studies in at least two appropriate animal species (in the absence of other animal or human data suggesting a potential for cancer effects);
- convincing and extensive experimental evidence showing that the only carcinogenic effects observed in animals are not relevant to humans;
- convincing evidence that carcinogenic effects are not likely by a particular exposure route; or
- convincing evidence that carcinogenic effects are not likely below a defined dose range.

The “Not Likely” descriptor applies only to the circumstances supported by the data. For example, an agent may be “Not Likely to Be Carcinogenic” by one route but not necessarily by another. In those cases that have positive animal experiment(s) but the results are judged to be not relevant to humans, the narrative discusses why the results are not relevant.

International Agency for Research on Cancer (IARC)

IARC-1: Carcinogenic to Humans — The exposure circumstance entails exposures that are carcinogenic to humans. This category is used when there is *sufficient evidence* of carcinogenicity in humans. Exceptionally, an agent (mixture) may be placed in the category when evidence in humans is less than sufficient but there is *sufficient evidence* of carcinogenicity in experimental animals and strong evidence in exposed humans that the agent (mixture) acts

through a relevant mechanism of carcinogenicity.

- 2A: Probably Carcinogenic to Humans — The exposure circumstance entails exposures that are probably carcinogenic to humans. This category is used when there is *limited evidence* of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals. In some cases, an agent (mixture) may be classified in this category when there is inadequate evidence of carcinogenicity in humans and *sufficient evidence* of carcinogenicity in experimental animals and strong evidence that the carcinogenesis is mediated by a mechanism that also operates in humans. Exceptionally, an agent, mixture, or exposure circumstance may be classified in this category solely on the basis of limited evidence of carcinogenicity in humans.
- 2B: Possibly Carcinogenic to Humans — The exposure circumstance entails exposures that are possibly carcinogenic to humans. This category is used for agents, mixtures, and exposure circumstances for which there is *limited evidence* of carcinogenicity in humans and less than *sufficient evidence* of carcinogenicity in experimental animals. It may also be used when there is *inadequate evidence* of carcinogenicity in humans but there is *sufficient evidence* of carcinogenicity in experimental animals. In some instances, an agent, mixture, or exposure circumstance for which there is inadequate evidence of carcinogenicity in humans but *limited evidence* of carcinogenicity in experimental animals together with supporting evidence from other relevant data may be placed in the group.
- 3: Unclassifiable as to Carcinogenicity in Humans — This category is used most commonly for agents, mixtures, and exposure circumstances for which the evidence of carcinogenicity is inadequate in humans and inadequate or limited in experimental animals. Exceptionally, agents (mixtures) for which the evidence of carcinogenicity is inadequate in humans but sufficient in experimen-

tal animals may be placed in this category when there is strong evidence that the mechanism of carcinogenicity in experimental animals does not operate in humans. Agents, mixtures, and exposure circumstances that do not fall into any other group are also placed in this category.

- 4: Probably Not Carcinogenic to Humans — This category is used for agents or mixtures for which there is *evidence suggesting lack of carcinogenicity* in humans and in experimental animals. In some instances, agents or mixtures for which there is *inadequate evidence* of carcinogenicity in humans but *evidence suggesting lack of carcinogenicity* in experimental animals, consistently and strongly supported by a broad range of other relevant data, may be classified in this group.

German MAK Commission

MAK-1: Substances that cause cancer in man and can be assumed to make a significant contribution to cancer risk. Epidemiological studies provide adequate evidence of a positive correlation between the exposure of humans and the occurrence of cancer. Limited epidemiological data can be substantiated by evidence that the substance causes cancer by a mode of action that is relevant to man.

- 2: Substances that are considered to be carcinogenic for man because sufficient data from long-term animal studies or limited evidence from animal studies substantiated by evidence from epidemiological studies indicate that they can make a significant contribution to cancer risk. Limited data from animal studies can be supported by evidence that the substance causes cancer by a mode of action that is relevant to man and by results of *in vitro* tests and short-term animal studies.

- 3: Substances which cause concern that they could be carcinogenic for man but cannot be assessed conclusively because of lack of data. The classification in Category 3 is provisional.

- 3A: Substances for which the criteria for classification in Category 4 or 5 are fulfilled but for which the database is insufficient for the establishment of a MAK value.

- 3B: Substances for which *in vitro* tests or animal studies have yielded evidence of carcinogenic effects that is not sufficient for classification of the substance in one of the other categories. Further studies are required before a final classification can be made. A MAK or BAT value can be established, provided no genotoxic effects have been detected.

- 4: Substances with carcinogenic potential for which genotoxicity plays no or at most a minor role. No significant contribution to human cancer risk is expected, provided the MAK value is observed. The classification is supported especially by evidence that increases in cellular proliferation or changes in cellular differentiation are important in the mode of action. To characterize the cancer risk, the manifold mechanisms contributing to carcinogenesis and their characteristic dose–time–response relationships are taken into consideration.

- 5: Substances with carcinogenic and genotoxic effects, the potency of which is considered to be so low that, provided the MAK and BAT values are observed, no significant contribution to human cancer risk is to be expected. The classification is supported by information on the mode of action, dose-dependence, and toxicokinetic data pertinent to species comparison.

U.S. National Institute for Occupational Safety and Health (NIOSH)

NIOSH-Ca: Potential occupational carcinogen, with no further categorization.

U.S. National Toxicology Program (NTP)

NTP-K: Known to Be a Human Carcinogen — There is sufficient evidence of carcinogenicity from studies in humans which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer.

OCCUPATIONAL EXPOSURE VALUES

xii

-R: Reasonably Anticipated to Be a Human Carcinogen (RAHC) — There is limited evidence of carcinogenicity from studies in humans, which indicates that causal interpretation is credible, but that alternative explanations, such as chance, bias or confounding factors, could not adequately be excluded;

OR

There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor, or age at onset;

OR

There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen or reasonably anticipated to be human carcinogen, or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.

U.S. Occupational Safety and Health Administration (OSHA)

OSHA-Ca: Carcinogen defined with no further categorization.

American Conference of Governmental Industrial Hygienists (ACGIH®)

TLV-A1: Confirmed Human Carcinogen — The agent is carcinogenic to humans based on the weight of evidence from epidemiologic studies.

-A2: Human data are accepted as adequate in quality but are conflicting or insufficient to classify the agent as a confirmed human carcinogen; or, the agent is

carcinogenic in experimental animals at dose(s), by route(s) of exposure, at site(s), of histologic type(s), or by mechanism(s) considered relevant to worker exposure. The A2 is used primarily when there is limited evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals is supported by mechanistic evidence of key characteristics of carcinogens that are relevant to humans.

-A3: Confirmed Animal Carcinogen with Unknown Relevance to Humans — The agent is carcinogenic in experimental animals at a relatively high dose, by route(s) of administration, at site(s), of histologic type(s), or by mechanism(s) that may not be relevant to worker exposure. Available epidemiologic studies do not confirm an increased risk of cancer in exposed humans. Available experimental animal evidence suggests mechanisms and/or dosimetry that the agent is unlikely to cause cancer in humans except under improbable routes or levels of exposure.

-A4: Not Classifiable as a Human Carcinogen — Agents which cause concern that they could be carcinogenic for humans, but which cannot be assessed conclusively because of a lack of human data. *In vitro* or animal studies do not provide mechanistic evidence of key characteristics of carcinogenicity which are sufficient to classify the agent into one of the other categories.

-A5: Not Suspected as a Human Carcinogen — The agent is not suspected to be a human carcinogen on the basis of properly conducted epidemiologic studies in humans. These studies have sufficiently long follow-up, reliable exposure histories, sufficiently high dose, and adequate statistical power to conclude that exposure to the agent does not convey a significant risk of cancer to humans; or, the evidence suggesting a lack of carcinogenicity in experimental animals is supported by mechanistic data demonstrating a lack of the key characteristics of carcinogenicity.

Substances for which no human or experimental animal carcinogenicity data are available and no strong genotoxicity data have been reported are assigned no carcinogenicity designation.

Exposure to carcinogens must be kept to a minimum. Worker exposures to A1 carcinogens without a TLV should be eliminated to the fullest extent possible. For A1 carcinogens with a TLV and for A2 and A3 carcinogens, worker exposure by all routes should be carefully controlled to levels as low as possible below the TLV as indicated by the (L) endnote in the TLV Table.

Notations

A–D listed in DFG MAK column only refers to Pregnancy Risk Group Classifications; see page xv for definitions.

(D) “Inert” gas or vapor that acts primarily as a simple asphyxiant without other significant physiologic effects when present in high concentrations in air.

DSEN May cause dermal sensitization. This notation is used to indicate the potential for dermal sensitization resulting from the interaction of an absorbed agent and ultraviolet light (i.e., photosensitization).

DSEN TLV Potential for worker sensitization by dermal contact as confirmed by available human or animal data.

E The value is for particulate matter containing no asbestos and < 1% Crystalline silica.

(EX) Explosion hazard. The substance is a flammable asphyxiant or excursions above the TLV® could approach 10% of the lower explosive limit.

(F) Respirable fibers. Length > 5 µ; aspect ratio ≥ 3:1, as determined by the membrane filter method at 400–450x magnification (4-mm objective), using phase-contrast illumination.

G As measured by the vertical elutriator, cotton-dust sampler. See Cotton Dust TLV® Documentation.

(H) Aerosol only.

I Measured as Inhalable fraction of the aerosol.

IFV Measured as Inhalable fraction and vapor.

(J) Does not include stearates of toxic metals.

(K) Should not exceed 2 mg/m³ respirable particulate.

L Exposure to carcinogens must be kept to a minimum. Workers exposed to A1 carcinogens without a TLV® should be properly equipped to eliminate to the fullest extent possible all exposure to the carcinogen. For A2 and A3 carcinogens without a TLV®, worker exposure by all routes should be carefully controlled. See the ACGIH® carcinogen definitions starting on the previous page.

(O) Sampled by method that does not collect vapor.

OTO Ototoxicant. The designation “OTO” for hearing disorders in the “Notations” column highlights the potential for a chemical to cause hearing impairment alone or in combination with noise, even below 85 dBA.

P Avoid prolonged and repeated skin contact to diesel fuels which can lead to dermal irritation and may be associated with an increased risk of skin cancer.

Q Absorbed rapidly through the skin in molten or heated liquid form in amounts that have caused rapid death in humans.

R Measured as respirable fraction of the aerosol.

RSEN May cause respiratory sensitization.

RSEN TLV Potential for worker sensitization by inhalation exposure as confirmed by available human or animal data.

Sa MAK–danger of sensitization of the airways.

SEN TLV Confirmed potential for worker sensitization as a result of dermal contact and/or inhalation exposure, based on the weight of scientific evidence.

Sh MAK–danger of sensitization of the skin.

Sah MAK–danger of sensitization of the airways and the skin.

SP MAK–danger of photo-contact sensitization.

T Measured as thoracic fraction of the aerosol.

(V) Vapor fraction.

(W) Worker exposure by all routes should be minimized to the fullest extent possible.

OCCUPATIONAL EXPOSURE VALUES

1–5 listed in the DFG MAK column only refers to Germ Cell Mutagen classifications; see page xv for definitions.

Miscellaneous

- ACGIH® – American Conference of Governmental Industrial Hygienists
- ACGIH® TLVs® – ACGIH® Threshold Limit Values
- AIHA – American Industrial Hygiene Association
- AIHA WEELs – AIHA Workplace Environmental Exposure Levels
- BEI – ACGIH® has recommended a Biological Exposure Index or Indices (BEIs®) for this substance:
 - BEI_C = Cholinesterase Inhibiting Pesticides;
 - BEI_M = Methemoglobin Inducers; and
 - BEI_P = Polycyclic Aromatic Hydrocarbons (PAHs)
 all of which are contained in the BEI® section of the current TLVs® and BEIs® book. For proper application, read the BEI® Documentation for the substance.
- CAS – Chemical Abstracts Service Registry Number
- Ceiling (C) – The concentration that shall not be exceeded during any part of the working exposure
- MAK – Federal Republic of Germany Maximum Concentration Values at the Workplace
- NIC – Notice of Intended Changes
- NIOSH Ceiling – The exposure that shall not be exceeded during any part of the workday. If instantaneous monitoring is not feasible, the ceiling shall be assessed as a 15-minute TWA exposure (unless otherwise specified) that shall not be exceeded at any time during a workday.

- NIOSH RELs – U.S. National Institute for Occupational Safety and Health Recommended Exposure Limits. For NIOSH RELs, TWA indicates a time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek.
- NIOSH RMLs – NIOSH will no longer use the term REL for occupational carcinogens. Instead, NIOSH will use the term *risk management limit* for carcinogens or RML-CA. An RML-CA is the daily maximum 8-hour time-weighted average concentration of a carcinogen above which a worker should not be exposed. Chemicals determined to be occupational carcinogens will be identified and updated within this guide as established by NIOSH.
- OARS – Occupational Alliance for Risk Science
- OARS WEELs – OARS Workplace Environmental Exposure Levels
- OSHA PELs – U.S. Occupational Safety and Health Administration Permissible Exposure Limits
- Skin – Danger of cutaneous absorption
- STEL – Short-Term Exposure Limit. Usually a 15-minute time-weighted average (TWA) exposure that should not be exceeded at any time during a workday, even if the 8-hour TWA is within the TLV–TWA, PEL–TWA, or REL–TWA
- TLV–SL – Threshold Limit Value–Surface Limit. The concentration on workplace equipment and facility surfaces that is not likely to result in adverse effects following dermal exposure or incidental ingestion.
- TWA – Time-weighted average exposure concentration for a conventional 8-hour (TLV®, PEL) or up to a 10-hour (REL) workday and a 40-hour workweek
- () – Values/notations contained in parentheses under the ACGIH® TLV® column indicate that these are under review and that an NIC exists.

MAK EXCURSION FACTORS, MAXIMUM DURATION OF PEAKS, MAXIMUM NUMBER PER SHIFT, AND MINIMUM INTERVAL BETWEEN PEAKS

Category	Excursion Factor	Duration	Number per Shift	Interval ^A
I Substances for which local Irritant effects determine the MAK value, also respiratory allergens	1 ^B	15 min, average value ^C	4	1 hour
II Substances with systemic effects	2 ^B	15 min, average value	4	1 hour

^A Only for excursion factors > 1.

^B Default value, or a substance-specific value (maximum 8).

^C In certain cases, a momentary value (concentration that should not be exceeded at any time) can also be established.

MAK PREGNANCY RISK GROUP CLASSIFICATION

Group A: Damage to the embryo or foetus in humans has been unequivocally demonstrated and is to be expected even when MAK and BAT values are observed.

Group B: According to currently available information, damage to the embryo or foetus must be expected even when MAK and BAT values are observed.

Group C: There is no reason to fear damage to the embryo or foetus when MAK and BAT values are observed.

Group D: Either there are no data for an assessment of damage to the embryo or foetus or the currently available data are not sufficient for classification in one of the groups A–C.

MAK GERM CELL MUTAGENS (confirmed or suspected)*

1. Germ cell mutagens which have been shown to increase the mutant frequency in the progeny of exposed humans.
2. Germ cell mutagens which have been shown to increase the mutant frequency in the progeny of exposed mammals.
- 3A. Substances which have been shown to induce genetic damage in germ cells of humans or animals, or which produce mutagenic effects in somatic cells of mammals *in vivo* and have been shown to reach the germ cells in an active form.
- 3B. Substances which are suspected of being germ cell mutagens because of their genotoxic effects in mammalian somatic cells *in vivo*; in exceptional cases, substances for which there are no *in vivo* data but which are clearly mutagenic *in vitro* and structurally related to known *in vivo* mutagens.
4. Not applicable. (Category 4 carcinogenic substances are those with nongenotoxic mechanisms of action. By definition, germ cell mutagens are genotoxic. Therefore, a Category 4 for germ cell mutagens cannot apply. At some time in the future, it is conceivable that a Category 4 could be established for genotoxic substances with primary targets other than DNA [e.g., purely aneugenic substances] if research results make this seem sensible.)
5. Germ cell mutagens or suspected substances (according to the definition of Category 3A and 3B), the potency of which is considered to be so low that, provided the MAK value is observed, their contribution to genetic risk for humans is expected not to be significant.

*The Categories for classification of germ cell mutagens have been established by analogy with the categories for carcinogenic chemicals at the workplace.

2021 EDITIONS

PERFECT COMPANIONS

TLVs® and BEIs® Book

Available in Print and Digital Format!

Guide to Occupational Exposure Values

Available in Limited Quantity Print and Digital Format!

Order yours today at acgih.org/store,
by email at customerservice@acgih.org, or by fax at (513)742-3355.

ACGIH® members receive 20% off all ACGIH® *Signature Publications*
and FREE Shipping on all Publications!



Product ID: 0121
ISBN: 978-1-607261-45-2
© 2021
Member Price: \$43.96
Nonmember Price: \$54.95 + S/H


2021

Guide to Occupational Exposure Values

Compiled by
ACGIH®



ISBN: 978-1-607261-48-3
© 2021
Member Price: \$61.56
Nonmember Price: \$76.95 + S/H



3640 Park 42 Drive • Cincinnati, Ohio 45241
(513)742-2020 • acgih.org

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Abietic acid 514-10-3														Sh							
Acenaphthene 83-32-9																					EPA-A* IARC-3 *oral route
Acenaphthylene 208-96-8																					EPA-D
Acephate 30560-19-1																					EPA-C
Acetyrene 25732-74-5																					IARC-3
Acetaldehyde (Acetic aldehyde) 75-07-0			C 25	C 45	200	360			See Pocket Guide Apps. A and C				50	91	I (1) C 100 C 180 C; 5						EPA-B2 IARC-2B MAK-5 NIOSH-Ca NTP-R TLV-A2
Acetamide 60-35-5	1 IFV	2.24 IFV																			IARC-2B MAK-3B TLV-A3
Acetaminophen (paracetamol) 103-90-2																					IARC-3
Acetamiprid 135410-20-7	NIC-0.01 IFV	NIC-0.1 IFV																			

OCCUPATIONAL EXPOSURE VALUES

OCCUPATIONAL EXPOSURE VALUES

SUBSTANCE	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
CAS#	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	
Acetic acid	10	25	15	37	10	25			10	25	15	37	10	25	I (2)						
64-19-7														C							
Acetic anhydride	1	4	3		5	20					C 5	C 20	0.1	0.42	I (2)					TLV-A4	
108-24-7														C							
Acetone	250	594	500	1187	1000	2400			250	590			500	1200	I (2)					EPA-I TLV-A4	
67-64-1				BEI										B							
Acetone cyanohydrin				C 5* *as CN							C 1*	C 4*					2		5		
75-86-5				Skin								*15-min							Skin		
Acetonitrile	20	34			40	70			20	34			10	17	II (2)					EPA-CBD; D TLV-A4	
75-05-8				Skin											Skin; C						
Acetophenone	10	49															10			EPA-D	
98-86-2																					
2-Acetylaminofluorene (2-AAF)																				NIOSH-Ca NTP-R OSHA-Ca	
53-96-3						See 29 CFR 1910.1014				See Pocket Guide App. A											
Acetyl chloride																				EPA-D	
75-36-5																					
Acetylene											C 2500	C 2662									
74-86-2	Documentation withdrawn; see Appendix F in TLVs® and BEIs® book (D, EX)																				

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Acetylsalicylic acid (Aspirin) 50-78-2	5								5												
Aciclovir 59277-89-3																					IARC-3
Acridine Orange 494-38-2																					IARC-3
Acriflavinium chloride 8018-07-3																					IARC-3
Acrolein 107-02-8			C 0.1	C 0.23	0.1	0.25			0.1	0.25	0.3	0.8									EPA-I IARC-3 MAK-3B TLV-A4
	Skin								See Pocket Guide App. C												
Acrylamide 79-06-1	0.03 IFV				0.3				0.03												EPA-L IARC-2A MAK-2 NIOSH-Ca
	Skin; DSEN				Skin				See Pocket Guide App. A				Skin; Sh; 2								
Acrylic acid 79-10-7	2	5.9							2	6			10	30	I (1)						IARC-3 TLV-A4
	Skin								Skin				C								
Acrylic acid polymer, neutralized, cross-linked 9003-04-7													0.05 R		I (1)						MAK-4
													C								
Acrylonitrile (Vinyl cyanide) 107-13-1	2	4.3			2		C 10*		1		C 10*										EPA-B1 IARC-2B MAK-2 NIOSH-Ca
	Skin				Skin *15-min See 29 CFR 1910.1045				Skin *15-min See Pocket Guide App. A				Skin; Sh								NTP-R OSHA-Ca TLV-A3

OCCUPATIONAL EXPOSURE VALUES

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	
Actinomycin D 50-76-0																				IARC-3	
Adipic acid 124-04-9		5											2 I	I (2)							
														C							
Adiponitrile 111-69-3	2	8.8							4	18										EPA-D	
			Skin																		
Adriamycin®, Doxorubicin hydrochloride 23214-92-8																				IARC-2A NTP-R	
Aflatoxins 1402-68-2																				IARC-1; 2B* MAK-1 NTP-K *CAS: 6795-23-9	
														Skin; 3A							
Agaritine 2757-90-6																				IARC-3	
Alachlor 15972-60-8		1 IFV																		TLV-A3	
			DSEN																		
Aldicarb 116-06-3	0.0006*	0.005*															0.0001			EPA-D IARC-3 TLV-A4	
			*IFV																Skin		
			Skin; BEI _C																		



SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Aldrin 309-00-2	0.05	IFV			0.25				0.25				0.25	I	II (8)						EPA-B2 IARC-2A NIOSH-Ca TLV-A3
		Skin				Skin				Skin				Skin							
Aliphatic hydrocarbon gases, Alkanes [C₁–C₄]																					
Alkali persulfates																					
																Sah					
Allyl alcohol (AA) 107-18-6	0.5	1.19			2	5			2	5	4	10									MAK-3B TLV-A4
		Skin				Skin				Skin				Skin							
Allyl bromide 106-95-6	0.1	0.5	0.2	1.0																	TLV-A4
		Skin																			
Allyl chloride 107-05-1	1	3	2	6	1	3			1	3	2	6									EPA-C IARC-3 MAK-3B TLV-A3
		Skin												Skin							
Allyl glycidyl ether (AGE) 106-92-3	1	4.7					C 10	C 45	5	22	10	44									MAK-2 TLV-A4
										Skin				Skin; Sh							
Allyl isothiocyanate 57-06-7																			1		IARC-3
																			Skin; DSEN		

OCCUPATIONAL EXPOSURE VALUES

OCCUPATIONAL EXPOSURE VALUES

6

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELS				CARCINOGENICITY CATEGORY
	TWA ppm		STEL/CEIL(C) mg/m ³		TWA ppm		STEL/CEIL(C) mg/m ³		TWA ppm		STEL/CEIL(C) mg/m ³		TWA ppm		PEAK/CEIL(C) mg/m ³		TWA ppm		STEL/CEIL(C) mg/m ³		
Allyl isovalerate 2835-39-4																				IARC-3	
Allyl methacrylate 96-05-9	1	5.16																			
			Skin																		
1-(2-Allyloxy)-2-(2,4-dichlorophenyl)ethyl-1H-imidazole 35554-44-0													2 I		II (2)						
															Skin; C						
Allyl propyl disulfide 2179-59-1	0.5	3			2	12			2	12	3	18	2	12		I (1)					
			DSEN																		
Aluminum hydroxide 21645-51-2													4 I								
													1.5 R								
															D						
Aluminum oxide 1344-28-1					15*; 5**								4 I							MAK-2*	
			TLV® withdrawn; see Aluminum, metal and insoluble compounds										1.5 R							*Fibrous dust	
					*Total dust	**Respirable fraction									D						
Aluminum, metal and insoluble compounds 7429-90-5		1 R			15*; 5**				10*; 5**				4 I							IARC-1* TLV-A4	
													1.5 R							*production	
					*Total dust	**Respirable fraction			*Total dust	**Respirable fraction					D						
Aluminum, pyro powders and welding fumes, as Al									5												
Aluminum, soluble salts and alkyls, as Al									2												
			TLV® withdrawn; see Aluminum, metal and insoluble compounds																		

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Amaranth 915-67-3																					IARC-3
5-Aminoacenaphthene 4657-93-6																					IARC-3
2-Aminoanthraquinone 117-79-3																					IARC-3 NTP-R
p-Aminoazobenzene 60-09-3														Sh							IARC-2B
o-Aminoazotoluene 97-56-3													Skin; Sh; 3B								IARC-2B MAK-2 NTP-R
p-Aminobenzoic acid 150-13-0																	5				IARC-3
2-Aminobutanol 96-20-8													1	3.7	II (2)						
1-Amino-2,4-dibromoanthraquinone 81-49-2																					IARC-2B NTP-R
2-Amino-3,4-dimethyl- indazo[4,5-f]quinoline (MeIQ) 77094-11-2																					IARC-2B NTP-R

OCCUPATIONAL EXPOSURE VALUES

8

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
2-Amino-3,8-dimethyl-imidazo[4,5-f]quinoxaline (MeIQx) 77500-04-0																					IARC-2B NTP-R
3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) 62450-06-0																					IARC-2B
4-Aminodiphenyl 92-67-1													can also occur as vapor and aerosol Skin; 3A								IARC-1 MAK-1 NIOSH-Ca NTP-K
4-Aminodiphenylamine 101-54-2																					MAK-3B
2-Aminodipyrido[1,2-a:3',2'-d]imidazole (Glu-P-2) 67730-10-3																					IARC-2B
2-(2-Aminoethoxy) ethanol 929-06-6													0.2 0.87 I (1) Skin; Sh; C								
6-Amino-2-ethoxy-naphthalene 293733-21-8																					MAK-2
5-Amino-9-ethyl-carbazole 132-32-1																					MAK-3B
1-Amino-2-methyl-anthraquinone 82-28-0																					IARC-3 NTP-R

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
2-Amino-2-methyl-1-propanol 124-68-5													1	3.7*	II (2)						
															*can also occur as vapor and aerosol Skin; C						
2-Amino-6-methyldipyr- do[1,2-a:3',2'-d]imida- zole (Glu-P-1) 67730-11-4																					IARC-2B
2-Amino-3-methylimid- azo[4,5-f]quinoline (IQ) 76180-96-6																					IARC-2A NTP-R
2-Amino-1-methyl-6-phe- nylimidazo[4,5-b]pyridine (PhIP) 105650-23-5																					IARC-2B NTP-R
3-Amino-1-methyl-5H- pyrido[4,3-b]indole (Trp-P-2) 62450-07-1																					IARC-2B
2-Amino-3-methyl-9H- pyrido[2,3-b]indole (MeA-α-C) 68006-83-7																					IARC-2B
3-Aminomethyl-3,5,5- trimethyl cyclohexylamine (Isophorone diamine) 2855-13-2																					
2-Amino-5-(5-nitro-2- furyl)-1,3,4-thiadiazole 712-68-5																					IARC-2B

OCCUPATIONAL EXPOSURE VALUES

OCCUPATIONAL EXPOSURE VALUES

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
2-Amino-4-nitrophenol 99-57-0																					IARC-3
2-Amino-5-nitrophenol 121-88-0																					IARC-3
2-Amino-5-nitrothiazole 121-66-4																					IARC-3
p-Aminophenol 123-30-8															Sh						
3-Aminophenyl 591-27-5															Sh						
bis(4-Aminophenyl) ether (4,4'-Oxydianiline; 4,4'-Diaminodiphenyl) 101-80-4																					IARC-2B MAK-2 NTP-R
N-(3-Aminopropyl)-N dodecylpropane-1,3- diamine 2372-82-9													0.05 I		II (8)						
2-Aminopyridine 504-29-0	0.5	2			0.5	2			0.5	2											
4-Aminopyridine 504-24-5																					EPA-D

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
2-Amino-9H-pyrido [2,3-b]indole (A-α-C) 26148-68-5																					IARC-2B
Aminotris(methylene- phosphonic acid) 6419-19-8																	10				
11-Aminoundecanoic acid 2432-99-7																					IARC-3
Amitrole (3-Amino-1,2,4-triazole) 61-82-5	0.2								0.2				0.2 I		II (8)						IARC-3 TLV-A3 MAK-4 NIOSH-Ca NTP-R
Ammonia 7664-41-7	25	17	35	24	50	35			25	18	35	27	20	14	I (2)						
Ammonium acetate 631-61-8																					EPA-D
Ammonium chloride fume 12125-02-9	10		20						10		20										
Ammonium methacrylate 16325-47-6																					EPA-D
Ammonium perfluorooctanoate 3825-26-1	0.01																				TLV-A3
		Skin																			

OCCUPATIONAL EXPOSURE VALUES

OCCUPATIONAL EXPOSURE VALUES

12

SUBSTANCE	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
CAS#	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	
Ammonium persulfate, as S ₂ O ₈ 7727-54-0	0.1												Sah								
Ammonium sulfamate 7773-06-0	10				15*; 5**				10*; 5**												
					*Total dust **Respirable fraction				*Total dust **Respirable fraction												
Amsacrine 51264-14-3																			IARC-2B		
α-Amylase													Sa								
α-Amylcinnamaldehyde 122-40-7													Sh								
tert-Amyl methyl ether (TAME) 994-05-8	20	84																			
Angelicin plus ultra-violet A radiation 523-50-2																			IARC-3		
Aniline 62-53-3	2	7.6			5	19	and Homologs Skin				and Homologs See Pocket Guide App. A		2	7.7	II (2)				EPA-B2 IARC-3 MAK-4 NIOSH-Ca	TLV-A3	
			Skin; BEI										Skin; Sh; C								
Animal hair, epithelia and other materials derived from animals													Sah								

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Anisidine, o- isomer 90-04-0	0.1	0.5				0.5			0.5												IARC-2B MAK-2 NIOSH-Ca TLV-A3
	Skin; BEI _M				Skin				Skin See Pocket Guide App. A				Skin								
Anisidine, p- isomer 104-94-9	0.1	0.5				0.5			0.5												IARC-3 MAK-3B TLV-A4
	Skin; BEI _M				Skin				Skin				Skin								
Anisidine hydrochloride, o- isomer 134-29-2																					NTP-R
Anthanthrene 191-26-4																					IARC-3 MAK-2
													Skin								
Anthracene 120-12-7																					EPA-D IARC-3
Anthranilic acid 118-92-3																					IARC-3
Anthraquinone 84-65-1																					IARC-2B
Antimony [7440-36-0] and compounds, as Sb		0.5				0.5			0.5				and inorganic compounds excluding Stibine 3A								MAK-2
Antimony hydride (Stibine) 7803-52-3	(0.1)	(0.51)			0.1	0.5			0.1	0.5											
	NIC-0.005																				

OCCUPATIONAL EXPOSURE VALUES

14

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	PEAK/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	
Antimony oxide 1327-33-9														3B						MAK-2	
Antimony trioxide 1309-64-4	0.02 I																			IARC-2B TLV-A2* *production	
Antimony trisulfide 1345-04-6																				IARC-3	
ANTU (α-Naphthylthiourea) 86-88-4	0.3				0.3				0.3											IARC-3 MAK-3B TLV-A4	
		Skin													Skin						
Apholate 52-46-0																				IARC-3	
Apollo 74115-24-5																				EPA-C	
p-Aramide, fibrous dust 26125-61-1																				MAK-3B	
Aramite® 140-57-8																				EPA-B2 IARC-2B	
Argon 7440-37-1	Documentation withdrawn; see Appendix F in TLVs® and BEIs® book Simple asphyxiant (D)																				

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Aristolochic acid 313-67-7																					IARC-1 NTP-K
Arsenic [7440-38-2] and inorganic compounds (except arsine), as As	0.01				0.5**; 0.01*						C 0.002* *15-min					Skin; 3A					EPA-A IARC-1 MAK-1 NIOSH-Ca NTP-K OSHA-Ca TLV-A1
		BEI			**Organic cmpds *Inorganic cmpds 29 CFR 1910.1018 Inorganic cmpds				See Pocket Guide App. A												
Arsenic acid [7778-39-4] and its salts, as As	0.01															Skin; 3A					EPA-A IARC-1 MAK-1 NIOSH-Ca NTP-K OSHA-Ca TLV-A1
Arsenic pentoxide, as As 1303-28-2	0.01															Skin; 3A					MAK-1 TLV-A1
Arsenic trioxide, as As 1327-53-3	0.01															Skin; 3A					MAK-1 TLV-A1
Arsenous [13464-58-9] acid and its salts, as As	0.01															Skin; 3A					EPA-A IARC-1 MAK-1 NIOSH-Ca NTP-K OSHA-Ca TLV-A1
Arsine 7784-42-1	0.005	0.01			0.05	0.2					C 0.002* *15-min										NIOSH-Ca
									See Pocket Guide App. A												
Asbestos, all forms 1332-21-4; 12001-28-4; 12172-73-5; 77536-66-4; 77536-67-5; 77536-68-6; 13207-32-0		0.1 f/cc (F)			0.1 f/cc	1 f/cc*															EPA-A EPA-CaH* IARC-1 MAK-1 NIOSH-Ca NTP-K OSHA-Ca TLV-A1
																					*Libby amphibole asbestos
									*30-min See 29 CFR 1910.1001				See Pocket Guide Apps. A and C								

OCCUPATIONAL EXPOSURE VALUES

16

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	
Asphalt fume (Bitumen)	0.5 I as benzene-soluble aerosol								C 5* *15-min				1.5* II (2)* can also occur as vapor and aerosol * Also CAS 64741-56-6 and 64742-93-4. High-temperature processing, vapors and aerosols: straight-run bitumen, air-rectified bitumen, mastic asphalt ** CAS 64742-93-4 only. High-temperature processing, vapors and aerosols: bitumen, oxidized								IARC-2B*; 2A** MAK-2***; 3B**** NIOSH-Ca TLV-A4 * hard bitumens and emissions during mastic asphalt work; straight run bitumens emissions during road paving ** oxidized bitumens emissions during roofing *** 64742-93-4, bitumen, oxidized ****8052-42-4; 64741-56-6; 64742-93-4
8052-42-4	BEI _p								See Pocket Guide Apps. A and C				Skin; D*; 3B**								
Assure																					EPA-D
76578-14-8																					
Atrazine	2 I								5				1 I II (2) C								IARC-3 TLV-A3
1912-24-9																					
Attapulgite, fibrous dust (Palygorskite)																					IARC-2B*; 3** MAK-2 *> 5 µm **< 5 µm
12174-11-7																					
Auramine													Skin; 3B								IARC-1*; 2B MAK-2 *production
492-80-8																					
Auramine hydrochloride													Skin; 3B								MAK-2
2165-27-2																					
Aurothioglucose																					IARC-3
12192-57-3																					

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	
Azacitidine 320-67-2																					IARC-2A NTP-R
Azaserine 115-02-6																					IARC-2B
Azathioprine 446-86-6																					IARC-1 NTP-K
Azinphos-methyl 86-50-0	0.2	IFV			0.2				0.2				1	I		II (8)					TLV-A4
	Skin; DSEN; BEI _C				Skin				Skin				Skin; Sh; B								
tris(Aziridinyl)-p-benzo-quinone (Triaziquone) 68-76-8																					IARC-3
2-(1-Aziridinyl)ethanol 1072-52-2																					IARC-3
bis(1-Aziridinyl)morpho- linophosphine sulfide (Morzid) 2168-68-5																					IARC-3
tris(1-Aziridinyl)-phos- phine oxide 545-55-1																					IARC-3
2,4,6-tris(1-Aziridinyl)-s- triazine 51143-3																					IARC-3

OCCUPATIONAL EXPOSURE VALUES

18

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	
Aziridyl benzoquinone 800-24-8																					IARC-3
Azobenzene 103-33-3																					EPA-B2 IARC-3
Azodicarbonamide 123-77-3													0.02 I		I (1)						EPA-B2 IARC-3
													D								
Barium [7440-39-3] and soluble compounds, as Ba		0.5				0.5				0.5			0.5 I		II (8)						EPA-CBD*; NL**; D TLV-A4 *inhalation **oral
Barium sulfate 7727-43-7		5 I				15*; 5**				10*; 5**			4 I 0.3 R*		II (8)						MAK-4* *respirable fraction
			E			*Total dust **Respirable fraction				*Total dust **Respirable fraction			*multiplcated with the material density		C						
Bendiocarb 22781-23-3	0.011*	0.1*																			TLV-A4
		*IFV Skin; BEI _C																			
Benomyl 17804-35-2		1 I				15*; 5**															TLV-A3
		DSEN				*Total dust **Respirable fraction									Sh; 3A						
Centazon (Basagran) 25057-89-0																					EPA-NL; E
11H-Benz[bc]acean- thylene 202-94-8																					IARC-3

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELS				CARCINOGENICITY CATEGORY	
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)			
	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³		
Benz[j]aceanthrylene 202-33-5																					IARC-2B	
Benz[l]aceanthrylene 211-91-6																					IARC-3	
Benz[a]acridine 225-11-6																					IARC-3	
Benz[c]acridine 225-51-4																					IARC-3	
Benzal chloride (Benzyl dichloride) 98-87-3														Skin							IARC-2A MAK-2	
Benzaldehyde 100-52-7																	2		4	DSEN		
Benz[a]anthracene 56-55-3														Skin; 3A							EPA-B2 IARC-2B MAK-2 NTP-R	TLV-A2
Benzene 71-43-2	0.5	1.6	2.5	8	1*	3*	5*	15*	0.1		1										EPA-A; K IARC-1 MAK-1 NIOSH-Ca	NTP-K OSHA-Ca TLV-A1
					*Table Z-2 for exclusions in 29 CFR 1910.1028(d) See 29 CFR 1910.1028				See Pocket Guide App. A				Skin; 3A									
Benzidine 92-87-5														and its salts Skin							EPA-A IARC-1* MAK-1 NIOSH-Ca *including dyes metabolized to Benzidine	NTP-K OSHA-Ca TLV-A1

OCCUPATIONAL EXPOSURE VALUES

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
1,2-Benzisothiazol-3(2H)-one 2634-33-5														Sh							
Benzo[b]chrysene 214-17-5																					IARC-3
Benzo[g]chrysene 196-78-1																					IARC-3
Benzo[a]fluoranthene 203-33-8																					IARC-3
Benzo[b]fluoranthene 205-99-2															Skin; 3B						EPA-B2 IARC-2B MAK-2 NTP-R TLV-A2
Benzo[ghi]fluoranthene 203-12-3																					IARC-3
Benzo[j]fluoranthene 205-82-3															Skin; 3B						IARC-2B MAK-2 NTP-R
Benzo[k]fluoranthene 207-08-9															Skin; 3B						EPA-B2 IARC-2B MAK-2 NTP-R
Benzo[a]fluorene 236-84-6																					IARC-3

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Benzo[b]fluorene 243-17-4																					IARC-3
Benzo[c]fluorene 205-12-9																					IARC-3
Benzofuran 271-89-6																					IARC-2B
Benzoic acid 65-85-0	NIC-0.5 IFV												0.5 R*		II (4)						EPA-D
	NIC-Skin; A5												*can also occur as vapor and aerosol Skin; C								
Benzoic acid alkali salts													10 I		II (2)						
													causes pseudoallergic reactions Skin; C								
Benzo[b]naphtho- [2,1-d]-thiophene 239-35-0																					IARC-3 MAK-2
													Skin; 3B								
Benzo[ghi]perylene 191-24-2																					EPA-D IARC-3
Benzo[c]phenanthrene 195-19-7																					IARC-2B
Benzophenone 119-61-9																	0.5				IARC-2B

OCCUPATIONAL EXPOSURE VALUES

22

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Benzo[a]pyrene 50-32-8					0.2				0.1												EPA-CaH IARC-1 MAK-2 NIOSH-Ca
		L; BEI _p			See Coal tar pitch volatiles				Coal tar pitch volatiles, Cyclo-hexane-extractable fraction See Pocket Guide Apps. A and C				Skin; 2								
Benzo[e]pyrene 192-97-2																					IARC-3
Benzoquinone dioxime, p- isomer 105-11-3																					IARC-3
1 H-Benzotriazole 95-14-7													can also occur as vapor and aerosol Skin								MAK-3B
Benzotrichloride (Benzyl trichloride) 98-07-7			C 0.1	C 0.8																	EPA-B2 IARC-2A MAK-2 NTP-R
		Skin											Skin								
Benzoyl chloride 98-88-4			C 0.5	C 2.8														C 5			IARC-2A MAK-3B TLV-A4
																	Skin; DSEN				
Benzoyl peroxide (Dibenzoyl peroxide) 94-36-0	5				5				5				5 I		I (1)						IARC-3 TLV-A4
Benzyl acetate 140-11-4	10	61																			IARC-3 TLV-A4
Benzyl alcohol 100-51-6													5	22*	I (2)		10				
													*can also occur as vapor and aerosol Skin; C								

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	
Benzyl chloride 100-44-7	1	5.2			1	5					C 1*	C 5*									EPA-B2 IARC-2A MAK-2 TLV-A3
Benzylhemiformal 14548-60-8																					
Benzyl Violet 4B 1694-09-3																					IARC-2B
Beryllium [7440-41-7] and compounds, as Be	0.00005 I				0.002**		C 0.005**; 0.025**; 0.0002					C 0.0005									EPA-B1; L*; IARC-1 MAK-1 NIOSH-Ca NTP-K TLV-A1 *inhaled **ingested
							*30 min peak per 8-hr shift ** This standard applies to any operations or sectors for which the exposure limits in the Beryllium standard, 1910.1024, are stayed or are otherwise not in effect.														
Biphenyl (Diphenyl) 92-52-4	0.2	1.3			0.2	1			0.2	1											EPA-S MAK-3B
Bismuth telluride, Undoped 1304-82-1	10				15*; 5**				10*; 5**												TLV-A4
Bismuth telluride, Se-doped, as Bi ₂ Te ₃ 1304-82-1	5								5												TLV-A4
Bisphenol A (4,4'-isopropylidenediphenol; BPA) 80-05-7																					

OCCUPATIONAL EXPOSURE VALUES

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	PEAK/CEIL(C) ppm	mg/m³	TWA ppm	mg/m³	STEL/CEIL(C) ppm	mg/m³	
Bisphenol A diglycidyl-ether (4,4'-Isopropylidenedi-phenol diglycidyl ether) 1675-54-3															Skin; Sh					IARC-3 MAK-3A	
Bisphenol A diglycidyl methacrylate 1565-94-2															Sh						
Bisphenol A glycerolate 4687-94-9															Sh						
Bisphenyl A ethoxylate dimethylacrylate 24448-20-2															Sh						
Bisphenyl F diglycidyl ether (o,o'-, o,p'-, p,p'- isomers) 54208-63-8; 57469-07-5; 2095-03-6															Sh						
Bisulfites																				IARC-3	
Bithionol 97-18-7															SP						
Cleomycins 41056-06-7																				IARC-2B	
Blue VRS 129-17-9																				IARC-3	

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Borate compounds, inorganic 1303-96-4; 1330-43-4; 10043-35-3; 12179-04-3	2 I		6 I										10 I* 0.75 I** B*; C**		I (1)* I (1)**						TLV-A4
									See Sodium tetraborate, anhydrous; Sodium tetraborate, decahydrate; and Sodium tetraborate, pentahydrate								*CAS: 10043-35-3 only **Tetraborates, as B				
Boron [7440-42-8] and compounds																					EPA-I
Boron oxide 1303-86-2	10				15*				10												
								*Total dust													
Boron tribromide 10294-33-4			C 0.7	C 7							C 1	C 10									
Boron trichloride 10294-34-5			C 0.7	C 2.4																	
Boron trifluoride 7637-07-2	0.1	0.28	C 0.7	C 1.95			C 1	C 3			C 1	C 3									
Boron trifluoride ethers 109-63-7; 353-42-4	0.1*		C 0.7*																		
				*as BF ₃																	
Brilliant Blue FCF, disodium salt 3841-45-9																					IARC-3

OCCUPATIONAL EXPOSURE VALUES

SUBSTANCE	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
CAS#	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	
Bromacil 314-40-9	10								110												TLV-A3
Bromate 15541-45-4																					EPA-L*; EPA- I**; EPA-B2 *oral route **inhalation
Bromelain 9001-00-7													Sa								
Brominated dibenzo- furans																					EPA-D
Bromine 7726-95-6	0.1	0.66	0.2	1.3	0.1	0.7			0.1	0.7	0.3	2									
Bromine pentafluoride 7789-30-2	0.1	0.72							0.1	0.7											
Bromobenzene 108-86-1																					EPA-II
Bromochloroacetic acid 5589-96-8																					IARC-2B
Bromochloroace- tonitrile 83463-62-1																					IARC-3

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
Bromodichloro- methane 75-27-4														Skin; 3B							EPA-B2 IARC-2B MAK-2 NTP-R
p-Bromodiphenyl ether 101-55-3																					EPA-D
Bromoform (Tribromomethane) 75-25-2	0.5	5.2			0.5	5			0.5	5											EPA-B2 IARC-3 MAK-3B TLV-A3
2,2-bis-(Bromomethyl)- 1,3-propanediol, tech- nical grade 3296-90-0																	0.2				IARC-2B NTP-R
2-Bromo-2-nitro-1,3- propanediol 52-51-7														Skin; Sh							
1-Bromopropane 106-94-5	0.1	0.5												Skin							IARC-2B MAK-2 NTP-R TLV-A3
Bromotrichloro- methane 75-62-7																					EPA-D
1,3-Butadiene 106-99-0	2	4.4			1	2.21	5	11						2							EPA-CaH* IARC-1 MAK-1 *inhaled
Butane, isomers 75-28-5; 106-97-8			1000*	2370*					800	1900			1000	2400	II (4)						NIOSH-Ca NTP-K TLV-A2
				*(EX)							CAS: 106-97-8 only			D							

OCCUPATIONAL EXPOSURE VALUES

OCCUPATIONAL EXPOSURE VALUES

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)		
	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	ppm	mg/m ³	
1,4-Butanediol diacrylate 1070-70-8														Sh							
1,4-Butanediol diglycidyl ether 2425-79-8														Sh							
1,4-Butanediol dimethacrylate 2082-81-7														Sh							
1,4-Butanediol dimethanesulfonate (Busulphan) 55-98-1																					IARC-1 NTP-K
1,4-Butane sultone 1633-83-6																					MAK-3B
2,4-Butane sultone 1121-03-5																					MAK-2
2-Butanethiol 513-53-1													2	7.48		II (2)					
																Skin; D					
n-Butanol (n-Butyl alcohol) 71-36-3	20	61			100	300					C 50	C 150	100	310		I (1)					EPA-D
											Skin					C					

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm		STEL/CEIL(C) mg/m³		TWA ppm		STEL/CEIL(C) mg/m³		TWA ppm		STEL/CEIL(C) mg/m³		TWA ppm		PEAK/CEIL(C) mg/m³		TWA ppm		STEL/CEIL(C) mg/m³		
sec-Butanol (sec-Butyl alcohol) 78-92-2	100	300			150	450			100	305	150	455									
tert-Butanol (tert-Butyl alcohol) 75-65-0	100	303			100	300			100	300	150	450	20	62	II (4)					TLV-A4	
															C						
Butenes, all isomers 106-98-9; 107-01-7; 115-11-7; 590-18-1; 624-64-6; 25167-67-3	250	574																		TLV-A4*	
																				*CAS: 115-11-7 only	
2-Butoxyethanol (EGBE) 111-76-2	20	97			50	240			5	24			10*	49	I (2)					EPA-NL IARC-3 TLV-A3	
			BEI				Skin				Skin										
2-Butoxyethyl acetate (EGBEA) 112-07-2	20	130							5	33			10*	66	I (2)					MAK-4 TLV-A3	
1-tert-Butoxy- 2-propanol 57018-52-7																				IARC-2B	
															C						
n-Butyl acetate 123-86-4					150	710			150	710	200	950	100	480	I (2)						
			TLV® and Documentation withdrawn; see Butyl acetates, all isomers												C						
sec-Butyl acetate 105-46-4					200	950			200	950											
			TLV® and Documentation withdrawn; see Butyl acetates, all isomers																		
tert-Butyl acetate 540-88-5					200	950			200	950			20	96	II (2)						
			TLV® and Documentation withdrawn; see Butyl acetates, all isomers												C						

OCCUPATIONAL EXPOSURE VALUES

30

SUBSTANCE	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY		
	TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		STEL/CEIL(C)		TWA		PEAK/CEIL(C)		TWA		STEL/CEIL(C)				
CAS#	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³	ppm	mg/m³			
Butyl acetates, all isomers 105-46-4; 110-19-0; 123-86-4; 540-88-5	50	238	150	712																			
n-Butyl acrylate (Acrylic acid ester, n-Butyl ester) 141-32-2	2	11							10	55			2	11		I (2)				IARC-3 TLV-A4			
	DSEN												Skin; Sh; C										
tert-Butyl acrylate 1663-39-4													Sh										
n-Butylamine 109-73-9			C 5	C 15			C 5	C 15			C 5	C 15	2	6.1		I (2) C 5 15							
	Skin				Skin				Skin				C										
sec-Butylamine 13952-84-6													2	6.1		I (2) C 5 15							
													D										
Butylated hydroxyani- sole (BHA) 25013-16-5													20 I				II (1)					IARC-2B MAK-3B NTP-R	
													C										
Butylated hydroxy- toluene (BHT; 2,6-Di-tert- butyl-p-cresol) 128-37-0	2 IFV								10				10 I		II (4) C							IARC-3 MAK-4 TLV-A4	
n-Butylbenzene 104-51-8													10		56		II (2) Skin; D						
2-Butyl-1,2-benziso- thiazolin-3-one 4299-07-4																	Sh						

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
4-tert-Butylbenzoic acid 98-73-7	0.1 I												2 I		II (2)						
	Skin												Skin; D								
Butyl benzyl phthalate 85-68-7													20 I		II (2)						EPA-C IARC-3
													C								
Butyl carbitol acetate (Diethylene glycol monobutyl ether acetate) 124-17-4													10	85	I (1.5)						
													C								
p-tert-Butylcatechol (4-[1,1-Dimethylethyl]-1,2-benzenediol) 98-29-3																			C 2		
													Sh				Skin; DSEN				
tert-Butylchloride 507-20-0																					EPA-D
n-Butyl chloroformate (Chloroformic acid butyl ester) 592-34-7													0.2	1.1	I (2)						
													C								
tert-Butyl chromate, as CrO₃ 1189-85-1			C 0.1		0.005				0.001*												NIOSH-Ca
	Skin				Skin				*as Cr(VI)												
					See 29 CFR 1910.1026				See Pocket Guide Apps. A and C												
n-Butyl glycidyl ether (PGE) 2426-08-6	3	16			50	270					C 5.6*	C 30*									MAK-3B
	Skin; DSEN										*15-min						Skin; Sh; 2				
tert-Butyl glycidyl ether 7608-72-7																					MAK-3B
													Skin; Sh								

OCCUPATIONAL EXPOSURE VALUES

32

SUBSTANCE CAS#	ACGIH® TLVs®				OSHA PELs				NIOSH RELs				DFG MAKs				AIHA & OARS WEELs				CARCINOGENICITY CATEGORY
	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	PEAK/CEIL(C) ppm	mg/m ³	TWA ppm	mg/m ³	STEL/CEIL(C) ppm	mg/m ³	
tert-Butyl hydroperoxide 75-91-2	0.1	0.4																			
		Skin																			
n-Butyl lactate 138-22-7	5	30							5	25											
n-Butyl mercaptan (Butanethiol) 109-79-5	0.5	1.8			10	35					C 0.5* *15-min	C 1.8*	0.5	1.9	I (1)						
n-Butyl methacrylate 97-88-1																					
															Sh						
o-sec-Butylphenol 89-72-5	5	31							5	30											
		Skin									Skin										
p-tert-Butylphenol 98-54-4													0.08	0.5	II (2)						
															Skin; Sh; D						
p-tert-Butyl phenyl glycidyl ether 3101-60-8															Sh						
p-tert-Butyltoluene 93-51-1	1	6.1			10	60			10	60	20	120									
iso-Butyl vinyl ether 109-63-5													20	83	I (1)						
															D						